Who is sponsoring NCT00019422?

NCT00019422 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT00019422?

Interventions in NCT00019422: carboplatin, lobradimil.

What condition does NCT00019422 study?

NCT00019422 studies Brain and Central Nervous System Tumors.

Is NCT00019422 still recruiting?

NCT00019422 is currently completed. Last updated 14 August 2013.

Last reviewed 2013-08-14 · How we verify

NCT00019422

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors

Completed Phase 2 Last updated 14 August 2013

What this trial tests

Phase 2 trial testing carboplatin in Brain and Central Nervous System Tumors. Completed in 1 April 2003.

Timeline

1 March 1998

1 April 2003

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Start date	1 March 1998
Estimated completion	1 April 2003
Sites	236 locations across United States, Australia, Canada, Netherlands, New Zealand, Puerto Rico, Switzerland

Drugs / interventions tested

carboplatin (Carboplatin) — full drug profile →
lobradimil — full drug profile →

Conditions studied

Brain and Central Nervous System Tumors — all drugs for Brain and Central Nervous System Tumors →

Sponsor

National Cancer Institute (NCI)

Who can join

Under 21, any sex, with Brain and Central Nervous System Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Lobradimil may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of carboplatin and lobradimil in treating children with brain tumors that have not responded to previous treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.
Nhàn NTT, Yamada T, Yamada KH. · · 2023 · cited 63× · PMID 37629112 · DOI 10.3390/ijms241612931
IL-17 Receptor Signaling Negatively Regulates the Development of Tubulointerstitial Fibrosis in the Kidney.
Ramani K, Tan RJ, Zhou D, Coleman BM, et al · · 2018 · cited 24× · PMID 30405320 · DOI 10.1155/2018/5103672

Verify or expand the search:

Other trials of carboplatin

Trials testing the same drug.

NCT07405190 — Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC · Phase 2 · not yet recruiting
NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT06694454 — Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun · Phase 1, PHASE2 · not yet recruiting
NCT07472517 — DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carbop · Phase 3 · not yet recruiting

Other recruiting trials for Brain and Central Nervous System Tumors

Currently open trials in the same condition.

NCT00978458 — Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma · Phase 3 · active not recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00019422 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 14 August 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00019422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing